Off-label treatment with Pasireotide and use of continuous glucose monitoring in late familial hyperinsulinemic hypoglycemia: a case report

Muthunayake, Suresha U; Feldt‐Rasmussen, Ulla; Ringholm, Lene

doi:10.1007/s00592-021-01723-9

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have also been reports of effective PAS treatment in patients with postprandial hypoglycemia (dumping syndrome) following bariatric surgery (Roux-en-Y gastric bypass) [ 101 ], familial hyperinsulinemic hypoglycemia [ 102 ], and diazoxide-resistant hyperinsulinism (congenital isolated hyperinsulinism) [ 103 ].…”

Section: Other Uses Of Pasireotidementioning

confidence: 99%

Pasireotide—a novel somatostatin receptor ligand after 20 years of use

Bolanowski

Kałużny

Witek

et al. 2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy in acromegaly than first-generation SRLs and to be efficacious in Cushing’s disease. The consequence of this binding profile is the increased blood glucose level in some patients. This results from the inhibition of both insulin secretion and the incretin effect and only a modest suppression of glucagon. A monthly intramuscular formulation of long-acting release pasireotide has been approved for both acromegaly and Cushing’s disease treatment. This review presents data on the efficacy and safety of pasireotide treatment mostly in patients with acromegaly and Cushing’s disease. Moreover, other possible therapeutic applications of pasireotide are mentioned.

show abstract

Section: Other Uses Of Pasireotidementioning

confidence: 99%